口服中成药治疗冠心病合并高脂血症的系统评价与网状Meta分析
本研究通过网状Meta分析评价8种口服中成药治疗冠心病合并高脂血症的疗效与安全性,纳入78项随机对照试验共7955例。结果显示中成药联合常规治疗可改善症状,但纳入研究证据质量整体偏低。
要点
- 脑心通胶囊联合常规治疗可改善心指数、心输出量并降低低密度脂蛋白胆固醇和总胆固醇。
- 通心络胶囊联合常规治疗可升高高密度脂蛋白胆固醇并降低甘油三酯。
- 血脂康胶囊联合常规治疗可提高总临床有效率。
核心结论
- 与单用常规治疗相比,中成药联合常规治疗可有效改善冠心病合并高脂血症患者的症状。
研究设计与样本
- 系统评价与网状Meta分析,检索PubMed、Embase、Cochrane Library、Web of Science、万方、维普、SinoMed和CNKI数据库。
- 共纳入78项随机对照试验,涉及7955例病例和8种中成药。
- 使用Cochrane风险偏倚评估工具评价纳入研究质量,采用R 4.2.1进行网状Meta分析。
主要发现
- 共24项随机对照试验报告了不良事件发生率,各研究中实验组与对照组不良事件发生率差异均无统计学意义(P > 0.05)。
- 所有研究无明显发表偏倚,但纳入随机对照试验的总体证据质量偏低。
- 亚组分析显示常规治疗方法的不同未导致结果异质性。
关键数值与推荐
- 纳入的8种中成药为通心络胶囊、脑心通胶囊、复方丹参滴丸、麝香保心丸、松龄血脉康胶囊、血脂康胶囊、银丹心脑通软胶囊和脂必泰胶囊。
- 脑心通胶囊联合常规治疗改善心指数和心输出量,并降低低密度脂蛋白胆固醇和总胆固醇水平。
- 通心络胶囊联合常规治疗升高高密度脂蛋白胆固醇水平并降低甘油三酯水平。
- 血脂康胶囊联合常规治疗提高总临床有效率。
临床怎么用
- 临床可考虑在常规治疗基础上联合口服中成药以改善冠心病合并高脂血症患者的症状。
- 选择中成药时需结合具体药物的效应特点,如脑心通胶囊侧重心功能与血脂指标,通心络胶囊侧重血脂谱调节。
- 应关注中成药联合常规治疗的不良事件发生情况,尽管各研究未发现统计学显著差异。
局限性
- 纳入随机对照试验的总体证据质量偏低。
- 仅24项随机对照试验报告了不良事件发生率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM OF THE STUDY: To evaluate the clinical efficacy and safety of commonly used oral Chinese patent medicines for the treatment of coronary heart disease combined with hyperlipidemia in clinical practice through a network meta-analysis. MATERIALS AND METHODS: PubMed, Embase, Cochrane Library, Web of Science, Wanfang, VIP, SinoMed, and CNKI databases were searched for all published randomized controlled trials (RCTs) on the treatment of coronary heart disease combined with hyperlipidemia using Chinese patent medicines. NoteExpress software was used to screen the literature obtained from the databases according to the inclusion and exclusion criteria. The Cochrane risk of bias assessment tool was used to evaluate the quality of the included studies. A network meta-analysis was performed using R 4.2.1. Subgroup analyses of outcome indicators were made based on conventional treatment (CT) methods. The incidence of adverse events in the included RCTs was statistically analyzed. A funnel plot was drawn using RevMan 5.4.1 software for the assessment of bias in the total clinical effectiveness rate. Finally, the quality of evidence for interventions with statistically significant differences was evaluated using the GRADE system. RESULTS: A total of 78 RCTs were included, involving 7,955 cases and 8 types of Chinese patent medicines, which were Tongxinluo Capsule, Naoxintong Capsule, Compound Danshen Dripping Pill, Shexiangbaoxin Pill, Songling Xuemaikang Capsule, Xuezhikang Capsule, Yindan Xinnaotong Capsule, and Zhibitai Capsule. A total of 24 RCTs reported the incidence of adverse events, but no statistically significant difference in the incidence of adverse events was found between the experimental and control groups in each study (P > 0.05). There was no obvious publication bias in all studies, but the overall quality of evidence in the included RCTs was low. Comparison of different intervention measures showed that Naoxintong Capsule + CT improved the cardiac index and cardiac output, and lowered the low-density lipoprotein cholesterol and total cholesterol levels. Tongxinluo Capsule + CT raised high-density lipoprotein cholesterol levels and reduced triglyceride levels. Xuezhikang Capsule + CT improved the total clinical effectiveness rate. Subgroup analyses showed that differences in CT did not cause heterogeneity in the results. CONCLUSION: Compared with the use of CT alone, the combined use of Chinese patent medicines with CT can effectively improve the symptoms in patients with both coronary heart disease and hyperlipidemia.
引用
- Yang Z, Li J, Zhou B, et al. Efficacy and safety of oral Chinese patent medicines in the treatment of coronary heart disease combined with hyperlipidemia: a systematic review and network meta-analysis of 78 trials. Chin Med. 2023. PMID: 38093294. doi:10.1186/s13020-023-00866-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。